
Imerys walked into its Q3 2026 release with the share price at €25.34, after a steady run over the past quarter that left many investors quietly optimistic. The headline was clear: the minerals specialist lifted full year adjusted earnings guidance, backed by €884m in quarterly revenue and a positive net profit from ongoing activities.
The stock reaction now pits emotion against arithmetic. Short term traders are fixating on near term profit pressure and past losses, while the updated guidance and improving operating trends tell a calmer story. That gap between fear and fundamentals is where today’s move really lives.
Love the higher full year earnings guidance from Imerys, but concerned about near term profit pressure and past losses clouding the picture? Compare this setup with a curated list of companies in our list of solid balance sheet and fundamentals stocks (202 results)
Imerys lifted full-year EBITDA guidance after steady Q3 momentum. Ask Charlie what’s really behind Imerys’ guidance upgrade.
For bullish investors, the key claim is that Imerys can shift from volume projects to efficiency and higher value minerals while keeping capital discipline tight.
"The main thing that has to go right is that Imerys continues to convert its pipeline in conductive additives and Graphite & Carbon into profitable sales growth while keeping tight capital discipline on large lithium and industrial projects."
Q3 adds evidence on the first leg of that story. Energy transition materials posted double digit YTD growth and Q3 organic expansion of 21%, outpacing the group and supporting the mix shift argument. Raised adjusted EBITDA guidance and a 9M margin of 7.1% indicate cost programs are feeding through, even while large lithium projects remain mothballed or partnered, in line with the capital discipline claim.
The price and this Narrative do not agree. → Uncover what this Narrative says Imerys is actually worth.
Bearish investors worry that repeated write downs turn Project Horizon from an efficiency engine into a repair job.
"Although Imerys is delivering Horizon savings that support current EBITDA, the EUR 41m impairment linked to this program signals that further footprint and cost actions may be less about upside and more about defending profitability."
Q3 delivery tells both sides of that story. Imerys lifts adjusted EBITDA guidance and reports a 7.1% 9M margin, so cost plans are clearly working. Yet the trailing 12 month net loss of €426.8m, driven in part by restructuring and project impairments, shows those fears are not fully neutralized by this improvement.
Imerys just showed how earnings headlines and trailing losses can send mixed messages across a single report. The real opportunity is finding stocks that could be undervalued before the market corrects them.
Those are three of them. See the full list of 201 companies trading below our fair value estimates →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com